Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Tafasitamab-cxix

(Monjuvi®)

Tafasitamab-cxix

Drug updated on 12/11/2024

Dosage FormInjection (intravenous; 200 mg)
Drug ClassCD19-directed cytolytic antibodies
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of three systematic review(s)/meta-analysis(es). [1-3]
  • Tafasitamab (TAFA) combined with lenalidomide (LEN) showed a median overall survival (OS) of 45.7 months in second-line treatment and 15.5 months in third-line treatment, significantly outperforming other therapies like Bendamustine-Rituximab (median OS 11.49 months, euro23 958 (BR)) with 11.49 months in second-line and Rituximab-Gemcitabine-Oxaliplatin (R-GemOx) with 12.0 months in third-line settings. TAFA + LEN also had significantly better OS compared to polatuzumab vedotin plus bendamustine and rituximab (POLA + BR) (hazard ratio (HR) 0.41; p = 0.026) and BR (HR 0.39; p = 0.014).
  • Progression-free survival (pooled data: HR 0.39 (95% confidence interval (CI) 0.29, 0.53 (PFS)) was improved in the tafasitamab group, with a 1-year PFS of 0.47 (95% CI, 0.37 to 0.57), higher than CAR T-cell therapy (0.40; 95% CI, 0.35 to 0.46) in autologous stem-cell transplant (ASCT)-ineligible patients. TAFA + LEN also showed a significantly better PFS compared to BR (HR 0.39; p < 0.001).
  • TAFA + LEN demonstrated a longer duration of response (DOR) compared to POLA + BR (HR 0.34; p = 0.045) and BR (HR 0.35; p < 0.001), along with an improved complete response rate (CRR) over BR (odds ratio 2.43; p = 0.004).
  • The reviewed studies did not explicitly mention safety outcomes or adverse effects related to tafasitamab-cxix or other drugs, so there is no safety information available.
  • Evidence highlights a distinction in effectiveness outcomes between ASCT-eligible and ASCT-ineligible groups. The 1-year progression-free survival (PFS) for tafasitamab in the ASCT-ineligible group was 0.47 (95% CI, 0.37 to 0.57), outperforming other therapies, including CAR T-cell therapy (PFS: 0.40, 95% CI, 0.35 to 0.46). No significant difference in PFS was observed between CAR T-cell therapy and chemotherapy followed by ASCT in the ASCT-eligible group.